| DESCRIPTION | - BRAHMER ET AL., J CLIN ONCOL, (2010), vol. 28, pages 3167 - 75 | - |
| DESCRIPTION | - BRAHMER ET AL., N ENGL J MED, (2012), vol. 366, pages 2455 - 65 | - |
| DESCRIPTION | - BURD, E., CLIN. MICROBIOL. REV., (200301), vol. 16, no. 1, pages 1 - 17 | - |
| DESCRIPTION | - HAMID; CARVAJAL, EXPERT OPIN BIOL THER, (2013), vol. 13, no. 6, pages 847 - 61 | - |
| DESCRIPTION | - HAMID ET AL., N ENGL J MED, (2013), vol. 369, pages 134 - 144 | - |
| DESCRIPTION | - HERBST ET AL., J CLIN ONCOL, (2013), vol. 31, page 3000 | - |
| DESCRIPTION | - HODI ET AL., N ENGL J MED, (2010), vol. 363, pages 711 - 23 | - |
| DESCRIPTION | - JOHNSON ET AL., CANCER IMMUNOL RES, (2013), vol. 1, pages 373 - 77 | - |
| DESCRIPTION | - MCDERMOTT; ATKINS, CANCER MED, (2013), vol. 2, no. 5, pages 662 - 73 | - |
| DESCRIPTION | - RINI ET AL., CANCER, (2011), vol. 117, pages 758 - 67 | - |
| DESCRIPTION | - SJOBLOM ET AL., SCIENCE, (2006), vol. 314, pages 268 - 74 | - |
| DESCRIPTION | - TOPALIAN ET AL., CIIRR OPIN IMMUNOL, (2012), vol. 24, pages 207 - 12 | - |
| DESCRIPTION | - TOPALIAN ET AL., CURR OPIN IMMUNOL, (2012), vol. 24, pages 207 - 12 | - |
| DESCRIPTION | - TOPALIAN ET AL., J CLIN ONCOL, (2014), vol. 32, no. 10, pages 1020 - 30 | - |
| DESCRIPTION | - TOPALIAN ET AL., N ENGL J MED, (2012), vol. 366, pages 2443 - 54 | - |
| DESCRIPTION | - WANG ET AL., CANCER IMMUNOL RES., (2014), vol. 2, no. 9, pages 846 - 56 | - |
| DESCRIPTION | - WOLCHOK ET AL., N ENGL J MED, (2013), vol. 369, no. 2, pages 122 - 33 | - |
| DESCRIPTION | - TAUBE, "Colocalization of inflammatory response with B7-hl expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape", SCI. TRANS!. MED., (2012), vol. 4, no. 127, doi:doi:10.1126/scitranslmed.3003689, page 127RA37, XP055123974 | |
| DESCRIPTION | - WANG ET AL., "In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates", CANCER IMM RES, (2014), vol. 2, no. 9, doi:doi:10.1158/2326-6066.CIR-14-0040, pages 846 - 56, XP055206944 | |
| INTERNATIONAL-SEARCH-REPORT | - Fury et al., "CLINICAL ACTIVITY AND SAFETY OF MEDI4736, AN ANTI-PD-L1 ANTIBODY, IN PATIENTS WITH HEAD AND NECK CANCER", (20140101), URL: http://annonc.oxfordjournals.org/content/25/suppl_4/iv341.1.short, (20161003), XP055307200 [X] 1,14-37,41,54-77 * abstract * | - |
| INTERNATIONAL-SEARCH-REPORT | - IBRAHIM R ET AL, "PD-L1 Blockade for Cancer Treatment: MEDI4736", SEMINARS IN ONCOLOGY, W.B. SAUNDERS, US, (20150601), vol. 42, no. 3, ISSN 0093-7754, pages 474 - 483, XP008181041 [X] 1,14-37,41,54-77 * table 1 * | - |
| INTERNATIONAL-SEARCH-REPORT | - LEE SYLVIA M ET AL, "A new addition to the PD-1 checkpoint inhibitors for non-small cell lung cancer-the anti-PDL1 antibody-MEDI4736.", TRANSLATIONAL LUNG CANCER RESEARCH DEC 2014, (201412), vol. 3, no. 6, ISSN 2218-6751, pages 408 - 410, XP002762500 [X] 1,14-37,41,54-77 * the whole document * | - |
| INTERNATIONAL-SEARCH-REPORT | - Seiwert et al, "Antitumor activity and safety of pembrolizumab in patients (pts) with advanced squamous cell carcinoma of the head and neck (SCCHN): Preliminary results from KEYNOTE-012 expansion cohort. -- Seiwert et al. 33 (18): LBA6008 -- ASCO Meeting Abstracts", (20150529), URL: http://meeting.ascopubs.org/cgi/content/abstract/33/18_suppl/LBA6008, (20161003), XP055307194 [X] 1,14-37,41,54-77 * abstract * | - |
| INTERNATIONAL-SEARCH-REPORT | - SEIWERT TANGUY Y ET AL, "Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial.", THE LANCET. ONCOLOGY JUL 2016, (201607), vol. 17, no. 7, ISSN 1474-5488, pages 956 - 965, XP002762502 [XP] 1-80 * the whole document * | - |
| INTERNATIONAL-SEARCH-REPORT | - Tabernero et al, "Clinical Activity, safety and Biomarkers of MPDL3280A, and Engineered PD-L1 Antibody with Locally Advanced or Metastatic Colorectal Cancer(CRC), Gastric Cancer(GC), Squamous cell Carcinoma of the Head and Neck (SCCHN) or other tumors.", (20130531), URL: http://carolinabiooncology.org/wp-content/uploads/2013/11/ASCO-2013-Poster-MPDL3280A.pdf, (20160921), XP002762501 [X] 1,14-37,41,54-77 * abstract * | - |
| INTERNATIONAL-SEARCH-REPORT | - JOEL SUNSHINE ET AL, "PD-1/PD-L1 inhibitors", CURRENT OPINION IN PHARMACOLOGY, NL, (20150602), vol. 23, doi:10.1016/j.coph.2015.05.011, ISSN 1471-4892, pages 32 - 38, XP055304528 [X] 1,14-37,41,54-77 * the whole document * | |
| INTERNATIONAL-SEARCH-REPORT | - DAN P. ZANDBERG ET AL, "The role of the PD-L1:PD-1 pathway in squamous cell carcinoma of the head and neck", ORAL ONCOLOGY, GB, (20140701), vol. 50, no. 7, doi:10.1016/j.oraloncology.2014.04.003, ISSN 1368-8375, pages 627 - 632, XP055304459 [Y] 1-80 * the whole document * | |
| INTERNATIONAL-SEARCH-REPORT | - ROY S. HERBST ET AL, "Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients", NATURE, United Kingdom, (20141126), vol. 515, no. 7528, doi:10.1038/nature14011, ISSN 0028-0836, pages 563 - 567, XP055262130 [X] 1,14-37,41,54-77 * the whole document * | |
| INTERNATIONAL-SEARCH-REPORT | - M. K. KECK ET AL, "Integrative Analysis of Head and Neck Cancer Identifies Two Biologically Distinct HPV and Three Non-HPV Subtypes", CLINICAL CANCER RESEARCH, US, (20141209), vol. 21, no. 4, doi:10.1158/1078-0432.CCR-14-2481, ISSN 1078-0432, pages 870 - 881, XP055307196 [Y] 1-80 * the whole document * | |
| INTERNATIONAL-SEARCH-REPORT | - R. STEWART ET AL, "Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody", CANCER IMMUNOLOGY RESEARCH, US, (20150901), vol. 3, no. 9, doi:10.1158/2326-6066.CIR-14-0191, ISSN 2326-6066, pages 1052 - 1062, XP055247766 [XP] 1,14-37,41,54-77 * the whole document * | |
| INTERNATIONAL-SEARCH-REPORT | - HAYES D NEIL ET AL, "Genetic Landscape of Human Papillomavirus-Associated Head and Neck Cancer and Comparison to Tobacco-Related Tumors", JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, USA, vol. 33, no. 29, doi:10.1200/JCO.2015.62.1086, ISSN 1527-7755, (20151010), pages 3227 - 3234, (20150908), XP008181725 [YP] 1-80 * the whole document * | |
| OPPOSITION | - ANG et al., "Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer", N Engl J Med., (20100701), vol. 363, no. 1, pages 24 - 35, XP055857372 | - |
| OPPOSITION | - Anonymous, "A Phase 1/2 study to evaluate MEDI4736", ClinicalTrials.gov Identifier: NCT01693562, (20120926), pages 1 - 26, URL: https: / / clinicaltrials.gov/ct2/show/NCT01693562, XP055857249 | - |
| OPPOSITION | - Anonymous, "ASCO 2016: Nivolumab Immunotherapy Improves Survival, Quality of Life in Metastatic or Recurrent Head and Neck Cancer", The ASCO Post, (20160101), pages 1 - 4, The ASCO Post, URL: https://ascopost.com/News/41639, (20211115), XP055861509 | - |
| OPPOSITION | - Anonymous, "Cervista™ HPV HR", Hologic Inc.,, pages 1 - 39 | - |
| OPPOSITION | - Anonymous, "ESMO 2014 Congress Scientific Meeting Report - Head and Neck Cancer Extract 26-30 Sept. 2014 Madrid Spain", Oncology Pro, (20140101), pages 1 - 7, XP055854128 | - |
| OPPOSITION | - Anonymous, "ESMO 2014", ESMO CONFERENCES, (20140928), pages 1 - 2, URL: https://cslide.ctimeetingtech.com/library/esmo/browse/itinerary/47 8/ 2014-09-28 #9f9D, XP055857270 | - |
| OPPOSITION | - Anonymous, "First Presentation of Early Data for Pembrolizumab (MK-3475), Merck’s Investigational Anti-PD-1 Antibody, in Advanced Head and Neck Cancer at ASCO 2014", Business Wire, (20140601), pages 1 - 4, Business Wire, URL: https://www.businesswire.com/news/home/20140601005057/en/First-Presentation-of-Early-Data-for-Pembrolizumab-MK-3475-Merck’s-Investigational-Anti-PD-1-Antibody-in-Advanced-Head-and-Neck-Cancer-at-%20ASCO-2014, (20211119), XP055863460 | - |
| OPPOSITION | - Anonymous, "History of Changes for Study: NCT01772004", clinicalTrail.gov, (20150520), pages 1 - 2, clinicalTrail.gov, URL: https://clinicaltrials.gov/ct2/history/NCT01772004?V10=View#StudyPageTop, (20211119), XP055863595 | - |
| OPPOSITION | - Anonymous, "History of Changes for Study: NCT01848834", ClinicalTrials.gov, (20150409), pages 1 - 2, ClinicalTrials.gov, URL: https://clinicaltrials.gov/ct2/history/NCT01848834?V33=View#StudyPageTop, (20211119), XP055863564 | - |
| OPPOSITION | - Anonymous, "History of Changes for Study: NCT01848834 Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-012/KEYNOTE-012)", CLINICALTRIALS.GOV Archive, (20140603), pages 1 - 5, XP055865449 | - |
| OPPOSITION | - Anonymous, "History of Changes for Study: NCT02291055 Phase 1-2 Study of ADXS11-001 or MEDI4736 Alone or Combo In Cervical or HPV+ Head & Neck Cancer", CLINICALTRIALS.GOV archive, (20141113), pages 1 - 4, XP055865417 | - |
| OPPOSITION | - Anonymous, "History of Changes for Study: NCT02426892 Nivolumab and HPV-16 Vaccination in Patients With HPV-16 Positive Incurable Solid Tumors", ClinicalTrials.gov, (20150428), pages 1 - 4, XP055865380 | - |
| OPPOSITION | - Anonymous, "Nivolumab and HPV-16 Vaccination in Patients With HPV-16 Positive Incurable Solid Tumors - Full Text View NCT02426892", ClinicalTrials.gov, (20150427), pages 1 - 8, ClinicalTrials.gov, URL: https://clinicaltrials.gov/ct2/show/NCT02426892, (20211116), XP055861917 | - |
| OPPOSITION | - Anonymous, "Pembrolizumab Shows Promise in Several Solid Tumours", ESMO 2014, (20140930), pages 1 - 5, ESMO 2014, URL: https://www.esmo.org/meetings/past- meetings/esmo-2014-congress/News-Articles/Pembrolizumab-Shows- Promise-in-Several-Solid-Tumours, (20211102), XP055857272 | - |
| OPPOSITION | - Anonymous, "Pembrolizumab Shows Promise in Several Solid Tumours", ESMO 2014, (20140930), pages 1 - 5, URL: https://www.esmo.org/meetings/past- meetings/esmo-2014-congress/News-Articles/Pembrolizumab-Shows- Promise-in-Several-Solid-Tumours, XP055857272 | - |
| OPPOSITION | - Anonymous, "Screenshot from ASCO Meeting Library 2015", ASCO Meeting Library, (20150601), URL: https://meetinglibrary.asco.org/browse- meetings/2015%20ASCO%20Annuai%20Meeting | - |
| OPPOSITION | - Anonymous, "Screenshot from ASCO Meeting Library", ASCO Meeting Library, (20150529), URL: https: //meetinglibrary.asco.org/browse- meetings/2015%20ASCO%20Annual%20Meeting | - |
| OPPOSITION | - Anonymous, "Study of MK-3475 (Pembrolizumab) in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Treatment With Platinum-based and Cetuximab Therapy (MK-3475-055/KEYNOTE-055) NCT02255097", ClinicalTrials.gov NCT02255097, (20141002), pages 1 - 12, ClinicalTrials.gov NCT02255097, URL: https://www.clinicaltrials.gov/ct2/show/NCT02255097, (20211115), XP055861552 | - |
| OPPOSITION | - Anonymous, "Study of Pembrolizumab (MK-3475) in participants with advanced solid tumors", ClinicalTrials.gov Identifier: NCT01848834, (20130508), pages 1 - 13, ClinicalTrials.gov Identifier: NCT01848834, URL: https://clinicaltrials.gov/ct2/show/NCT01848834, (20211102), XP055857256 | - |
| OPPOSITION | - Anonymous, "Study of Pembrolizumab (MK-3475) in participants with advanced solid tumors", ClinicalTrials.gov Identifier: NCT01848834, pages 1 - 13, ClinicalTrials.gov Identifier: NCT01848834, URL: https://clinicaltrials.gov/ct2/show/NCT01848834, (20211102), XP055857256 | - |
| OPPOSITION | - Anonymous, "Study of Pembrolizumab (MK-3475) in participants with advanced solid tumors", ClinicalTrials.gov Identifier: NCT01848834, URL: https://clinicaltrials.gov/ct2/show/NCT01848834, XP055857256 | - |
| OPPOSITION | - Anonymous, "Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141) NCT02105636", ClinicalTrials.gov, (20191001), pages 1 - 9, ClinicalTrials.gov, URL: https://clinicaltrials.gov/ct2/show/NCT02105636, (20211108), XP055858781 | - |
| OPPOSITION | - A video of the oral disclosure of Dr. Seiwert's presentation. | - |
| OPPOSITION | - Bamford Jennifer, Bamford Jennifer, Webster Rachel M, "FROM THE ANALYST'S COUCH The SCCHN drug market", Nature Reviews Drug Discovery, (20170401), pages 235 - 236, Nature Reviews Drug Discovery, URL: https://www.nature.com/articles/nrd.2016.261.pdf, (20211115), XP055861297 | - |
| OPPOSITION | - Baruah P, Et Al, "Impact of human papilloma virus (HPV) on stromal cells and programme death receptor/ligand pathway in head and neck squamous cell carcinoma (HNSCC) tumour microenvironment", Immunology, (20141201), vol. 143, page 168, XP055863586 | - |
| OPPOSITION | - Bauman J, Et Al, "Head and Neck Cancer Steering Committee Immunotherapy in Head & Neck Cancer Clinical Trials Planning Meeting", Head and Neck Cancer Steering Committee Immunotherapy in Head & Neck Cancer Clinical Trials Planning Meeting, (20141110), pages 1 - 5, XP055861544 | - |
| OPPOSITION | - BROWN et al., "Role of Protein Biomarkers in the Detection of High-Grade Disease in Cervical Cancer Screening Programs", Journal of Oncology, vol. 2012, pages 1 - 11, XP055857352 | - |
| OPPOSITION | - BURTNESS, "Moving Forward in the Management of Squamous Cell Carcinoma of the Head and Neck: Promising Immuno-Oncology Approaches", American Journal of Hematology/Oncology, (20151100), vol. 11, pages 28 - 31, XP055857334 | - |
| OPPOSITION | - CHOW et al., "A Phase IB Study of Pembrolizumab (PEMBRO; MK -3475) in Patients (PTS) with Human Papilloma Virus (HPV)-Positive and Negative Head and Neck Cancer (HNC", Annals of Oncology, (20140000), vol. 25, no. Supplement 5, pages v1 - v41, XP055854124 | - |
| OPPOSITION | - CHOW et al., "A phase IB study of pembrolizumab (pembro; MK -3475) in patients (pts) with human papilloma virus (HPV)-positive and negative head and neck cancer (HNC", Annals of Oncology, (20140900), vol. 25, no. suppl 5, pages v1 - v41, XP055854124 | - |
| OPPOSITION | - Chow L Q, Et Al, "A phase IB Study of Pembrolizumab (Pembro MK-3475) in Patients (PTS) with Human Papilloma Virus (HPV)-Positive and Negative Head and Neck Cancer (HNC)", Annals of Oncology, (20140101), vol. 25, pages 1 - 1, XP055854124 | - |
| OPPOSITION | - Chow L Q, Et Al, "A phase IB Study of Pembrolizumab (Pembro MK-3475) in Patients (PTS) with Human Papilloma Virus (HPV)-Positive and Negative Head and Neck VCancer (HNC)", Annals of Oncology, (20140101), vol. 25, pages 1 - 1, XP055854124 | - |
| OPPOSITION | - Cohen, Et Al, "KEYNOTE-040: A phase III randomized trial of pembrolizumab (MK-3475) versus standard treatment in patients with recurrent or metastatic head and neck cancer. ", Journal of Clinical Oncology, (20150101), pages 1 - 4, Journal of Clinical Oncology, URL: https://ascopubs.org/doi/10.1200/jco.2015.33.15_suppl.tps6084, (20211115), XP055861500 | - |
| OPPOSITION | - DE LARTIGUE, "Rising to the therapeutic challenge of head and neck cancer", Journal of Community and Supportive Oncology, (20150200), vol. 13, pages 73 - 80, XP055857321 | - |
| OPPOSITION | - Feldman R, Et Al, "1019P PD1 and PDL1 in HPV+ and HPV-/TP53 mutated head and neck squamos cell carc inomas", Annals of Oncology, (20140101), vol. 25, pages 1 - 1, XP055861286 | - |
| OPPOSITION | - FERRIS, "Nivolumab confers significant OS benefit in recurrent or metastatic head Wh and neck squamous cell carcinoma", Highlights from AACR Annual Meeting, XP055810815 | - |
| OPPOSITION | - Ferris Robert L, "Further evaluations of nivolumab (nivo) versus investigator’s choice (IC) chemotherapy for recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): CheckMate 141. ", Journal of Clinical Oncology, (20160101), pages 1 - 4, Journal of Clinical Oncology, URL: https://ascopubs.org/doi/10.1200/JCO.2016.34.15_suppl.6009, (20211116), XP055862053 | - |
| OPPOSITION | - Ferris Robert, "Nivolumab confers significant OS benefit in recurrent or metastatic head and neck squamous cell carcinoma", (20180416), URL: https://www.healio.com/news/hematology-oncology/20180416/nivolumab-confers-significant-os-benefit-in-recurrent-or-metastatic-head-and-neck-squamous-cell-carc, (20210607), XP055810815 | - |
| OPPOSITION | - Fury et al, "988PD CLINICAL ACTIVITY AND SAFETY OF MEDI4736, AN ANTI-PD-L1 ANTIBODY, IN PATIENTS WITH HEAD AND NECK CANCER", ANNALS OF ONCOLOGY, (20140101), URL: http://annonc.oxfordjournals.org/content/25/suppl_4/iv341.1.short, (20161003), XP055307200 | - |
| OPPOSITION | - FURY et al., "Clinical activity and safety of MEDI4736, an anti-PD-L1 antibody, in patients with head and neck cancer", ANNALS OF ONCOLOGY, (20140101), XP055307200 | - |
| OPPOSITION | - Goodman Alice, "Clinically Meaningful Preliminary Results With Pembrolizumab in Recurrent Head and Neck Cancer", The ASCO Post, (20151001), pages 1 - 4, The ASCO Post, URL: https://ascopost.com/issues/june-10-2015/clinically-meaningful-preliminary-results-with-pembrolizumab-in-recurrent-head-and-neck-cancer/, (20211119), XP055863452 | - |
| OPPOSITION | - HELLMAN et al., "Human papillomavirus, p161NK4A, and Ki-67 in relation to clinicopathological variables and survival in primary carcinoma of the vagina", British Journal of Cancer, (20140000), vol. 110, no. 6, pages 1561 - 1570, XP055857354 | - |
| OPPOSITION | - HOFFMAN J., "MEDI4736 Produces Durable Response in Squamous Cell Carcinoma of the Head and Neck", 2015 ASCO Annual Meeting, (20150530), pages 1 - 5, XP055857326 | - |
| OPPOSITION | - HONG et al., "Use of cyclin D1 in conjunction with human papillomavirus status to predict outcome in oropharyngeal cance r", Int. J. Cancer, (20110000), vol. 128, pages 1532 - 1545, XP055857355 | - |
| OPPOSITION | - HUGHES Debra, "Pembrolizumab Immunotherapy Effective in Recurrent, Metastatic Head and Neck Cancer", Cancer Therapy, (20150602), pages 1 - 4, XP055857280 | - |
| OPPOSITION | - Iarc Working Group On The Evaluation Of Carcinogenic Risks To Humans, "Human Papillomaviruses - NCBI NBK321760", Human Papillomaviruses, (20050101), pages 1 - 5, Human Papillomaviruses, URL: https://www.ncbi.nlm.nih.gov/books/NBK321760/, (20211115), XP055861268 | - |
| OPPOSITION | - IBRAHIM et al., "PD-L1 blockade for cancer treatment: MEDI4736", Seminars in oncology, (20150000), vol. 42, no. 3, pages 474 - 483, XP008181041 | - |
| OPPOSITION | - IBRAHIM et al., "PD-L1 Blockade for Cancer Treatment: MEDI4736", Seminars in Oncology, US, (20150601), vol. 42, no. 3, pages 474 - 483, XP008181041 | - |
| OPPOSITION | - Kenneth Murphy, "16-18 Checkpoint blockade can augment immune responses to existing tumors", Kenneth Murphy, Kenneth Murphy, Janeway's Immunobiology, 8th ed., UK, Garland Science, Taylor & Francis Group, LLC, (20120101), pages 694 - 697, ISBN 978-0-8153-4243-4, XP009556149 | - |
| OPPOSITION | - Kofler B, Et Al, "New Tratment strategies for HPV-positive head and neck cancer", Eur. Arch. Otorhinolaryngol., (20140101), vol. 271, pages 1861 - 1867, XP055854134 | - |
| OPPOSITION | - KOFLER et al., "New treatment strategies for HPV-positive head and neck cancer", Eur Arch Otorhinolaryngol, (20140000), vol. 271, pages 1861 - 1867, XP055854134 | - |
| OPPOSITION | - LEE et al., "A new addition to the PD-1 checkpoint inhibitors for non-small cell lung cancer - the anti-PDL1 antibody MEDI4736", Translational Lung Cancer Research, (20141200), vol. 3, no. 6, pages 408 - 410, XP002762500 | - |
| OPPOSITION | - LEE et al., "A new addition to the PD-1 checkpoint inhibitors for non-small cell lung cancer-the anti-PDL1 antibody-MEDI4736", Translational Lung Cancer Research, (20141200), vol. 3, no. 6, pages 408 - 410, XP002762500 | - |
| OPPOSITION | - M Fury et al.,, "988PD - CLINICAL ACTIVITY AND SAFETY OF MEDI4736, AN ANTI-PD-L1 ANTIBODY, IN PATIENTS WITH HEAD AND NECK CANCER", (20140101), URL: http://annonc.oxfordjournals.org/content/25/suppl_4/iv341.1.short, (20161003), XP055307200 | - |
| OPPOSITION | - Misiukiewicz Krzysztof, Et Al, "The role of HPV status in recurrent/metastatic squamous cell carcinoma of the head and neck", Clinical advances in hematology & oncology, (20141201), pages 812 - 819, Clinical advances in hematology & oncology, URL: https://www.hematologyandoncology.net/files/2014/12/misiukiewicz1.pdf, (20211115), XP055861548 | - |
| OPPOSITION | - Neil Howard Segal, Sai-Hong Ignatius Ou, Am Sarkis Baimanoukian, Matthew G Fury, Ermima Massarelii,Julie R Brahmer.Jare, "Screenshot : Safety and efficacy of MED 14736, an anti-PD-L1 antibody, in patients from a squamouscell carcinoma...", ASCO Meeting Library, (20150530), page 1 | - |
| OPPOSITION | - Nguyen Harrison P, Et Al, "The Biology of Human Papillomaviruses", Curr Probl Dermatol., (20140101), vol. 45, pages 19 - 32, XP055858796 | - |
| OPPOSITION | - Nindl Ingo, Et Al, "Distribution of 14 high risk HPV types in cervical intraepithelial neoplasia detected by a non-radioactive general primer PCR mediated enzyme immunoassay", J Clin Pathol, (19990101), pages 17 - 22, J Clin Pathol, URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC501002/pdf/jclinpath00274-0026.pdf, (20211119), XP055863587 | - |
| OPPOSITION | - "OPDIVO 10 mg/mL concentrate for solution for infusion", Summary of Product Characteristics | - |
| OPPOSITION | - Partlova et al, "Distinct patterns of intratumoral immune cell infiltrates in patients with HPV-associatedcompared to non-virally induced head and necksquamous cell carcinoma", Oncolmmunology, (20150101), vol. 4, no. 1, pages e965570 (1) - e965570 (12), XP055857287 | - |
| OPPOSITION | - PARTLOVA S., J. Boucek, K. Kloudova, E. Lukesova, M. Zabrodsky, M. Grega, J. Fucikova, I. Truxova, R. Tachezy, R. Spfsek, A. Fialova, "Distinct patterns of intratumoral immune cell infiltrates in patients with HPV-associatedcompared to non-virally induced head and necksquamous cell carcinoma", Oncolmmunology, (20150000), vol. 4, no. 1, pages e965570 (1) - e965570 (12), XP055857287 | - |
| OPPOSITION | - "Phase 1-2 Study of ADXS11-001 or MEDI4736 Alone or Combo In Cervical or HPV+ Head & Neck Cancer", Clinical Trial No. NCT02291055, (20150710), XP055857335 | - |
| OPPOSITION | - PIROG et al., "HPV prevalence and genotypes in different histological subtypes of cervical adenocarcinoma, a worldwide analysis of 760 cases", Modern Pathology, (20140000), vol. 27, pages 1559 - 1567, XP055857350 | - |
| OPPOSITION | - Rajasekaran N, Et Al, "Exploratory analysis of clinical and translational factors associated with the inflamed phenotype in HNSCC", Journal of Clinical Oncology, (20150520), vol. 33, no. 15 suppl, pages 1 - 2, XP055854131 | - |
| OPPOSITION | - ROBERT L. FERRIS, "Nivolumab confers significant OS benefit in recurrent or metastatic head and neck squamous cell carcinoma", AACR ANNUAL MEETING, Chicago, Illinois, (20180416), URL: https ://www.healio.com/news/hematology-oncology/ 20180416 /nivolu mab-confers-significant-os- benefit-in-recurrent-or-metastatic-head-and-neck-squamous- cell -carc, XP055810815 | - |
| OPPOSITION | - Sara I. Pai, "Mission impossible: How HPV-associated head and neck cancers escape a primed immune response", Oral Oncology, (20130101), vol. 49, no. 8, pages 723 - 725, XP055865466 | - |
| OPPOSITION | - Schache A. G., Thavaraj S., Croud J., Robinson M., "Human Papillomavirus Testing in Head and Neck Squamous Cell Carcinoma: Best Practice for Diagnosis", Methods in Molecular Biology, (20140700), vol. 1180, pages 237 - 255, XP055857328 | - |
| OPPOSITION | - SEGAL et al., "Safety and efficacy of MEDI4736, an anti-PD-L1 antibody, in patients from a squamous cell carcinoma of the head and neck (SCCHN) expansion cohort", Journal of Clinical Oncology, (20150520), vol. 33, no. 15, XP055857336 | - |
| OPPOSITION | - Segal Neil Howard, Et Al, "Safety and efficacy of MEDI4736, an anti-PD-L1 antibody, in patients from a squamous cell carcinoma of the head and neck (SCCHN) expansion cohort", Journal of Clinical Oncology, (20150520), vol. 33, no. 15, page 3011, XP055863581 | - |
| OPPOSITION | - Segal N. H et al, "Safety and efficacy of MEDI4736, an anti-PD-L1 antibody, inpatients from a squamous cell carcinoma of the head and neck (SCCHN) expansion cohort.", Journal of Clinical Oncology, (20150520), vol. 33, no. 15, pages 1 - 4, XP055857323 | - |
| OPPOSITION | - Segal N. H., Ou S. H. I., Balmanoukian A. S., Fury M. G., Massarelli E., Brahmer J. R. et al., "Safety and efficacy of MEDI4736, an anti-PD-L1 antibody, inpatients from a squamous cell carcinoma of the head and neck (SCCHN) expansion cohort.", Journal of Clinical Oncology, (20150520), vol. 33, no. 15, pages 1 - 4, XP055857323 | - |
| OPPOSITION | - Segal N. H., Ou S. H. I., Balmanoukian A. S., Fury M. G., Massarelli E., Brahmer J. R. Et Al., "Safety and efficacy of MEDI4736, an anti-PD-L1 antibody, inpatients from a squamous cell carcinoma of the head and neck (SCCHN) expansion cohort.", Journal of Clinical Oncology, (20150520), vol. 33, no. 15, pages 1 - 4, XP055857323 | - |
| OPPOSITION | - Segal N. H., Ou S. H. I., Balmanoukian A. S., Fury M. G., Massarelli E., Brahmer J. R., Weiss J., Schoffski P., Antonia S. J., Massard C., Zandberg D. P., Khleif S. N., Li X., Rebelatto M. C., Steele K. E., Robbins P. B., Blake-Haskins J. A., Butler M. O., "Safety and efficacy of MEDI4736 , an Anti-PD L1 Antibody, in patients from a squamous cell carcinoma of the head and neck (SCCHN) expansion cohort", ASCO Annual Meeting 2015 (poster), (20150529), page 1, XP055857320 | - |
| OPPOSITION | - Seiwert, "Antitumor activity and safety of pembrolizumab in patients (pts) with advanced squamous cell carcinoma of the head and neck (SCCHN): Preliminary results from KEYNOTE-012 expansion cohort. -- Seiwert et al. 33 (18): LBA6008 -- ASCO Meeting Abstracts", (20150529), URL: http://meeting.ascopubs.org/cgi/content/abstract/33/18_suppl/LBA6008, (20161003), XP055307194 | - |
| OPPOSITION | - SEIWERT et al., "Antitumor activity and safety of pembrolizumab in patients (pts) with advanced squamous cell carcinoma of the head and neck (SCCHN): Preliminary results from KEYNOTE-012 expansion cohort", Journal of Oncology, vol. 33, no. 18, (20150620), XP055857341 | - |
| OPPOSITION | - SEIWERT et al., "A phase IB study of MK -3475 in patients with human papillomavirus (HPV)- associated and non-HPV-associated head and neck (H/N) cancer [abstract", Journal of Clinical Oncology, (20140520), vol. 32, no. 15, pages 6011 - 6011, XP055857329 | - |
| OPPOSITION | - SEIWERT et al., "A phase Ib study of MK -3475 in patients with human papillomavirus (HPV)-associated and non-HPV-associated head and neck (H/N) cancer", Journal of Clinical Oncology, (20140000), vol. 32, no. 15, XP055857329 | - |
| OPPOSITION | - Seiwert Tanguy, Et Al, "A phase IB study of MK -3475 in patients with human papillomavirus (HPV)- associated and non-HPV-associated head and neck cancer", (20140603), pages 1 - 22, XP055861232 | - |
| OPPOSITION | - Seiwert Tanguy V et al, "A phase Ib study of MK -3475 in patients with human papillomavirus (HPV)-associated and non-HPV-associated head and neck (H/N) cancer", Journal of Clinical Oncology, (20140101), vol. 32, no. 15 supp, XP055857329 | - |
| OPPOSITION | - SEIWERT TANGUY Y ET AL, "Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial.", The Lancet Oncology, Elsevier Ltd, (20160701), vol. 17, no. 7, ISSN 1474-5488, pages 956 - 965, XP002762502 | - |
| OPPOSITION | - Siewert Tanguy Y., Haddad Robert I., Gupta Shilpa, Mehra Ranee, Tahara Makoto, Berger Raanan Et Al., "Antitumor activity and safety of pembrolizumab in patients (pts) with advanced squamous cell carcinoma of the head and neck (SCCHN): Preliminary results from KEYNOTE-012 expansion cohort. -- Seiwert et al. 33 (18): LBA6008 -- ASCO Meeting Abstracts", Journal of Clinical Oncology, (20150529), vol. 33, no. 18, pages 1 - 3, XP055307194 | - |
| OPPOSITION | - Siewert T; Et Al, "Antitumor activity and safety of pembrolizumab in patients (pts) with advanced squamous cell carcinoma of the head and neck (SCCHN): Preliminary results from KEYNOTE-012 expansion cohort. -- Seiwert et al. 33 (18): LBA6008 -- ASCO Meeting Abstracts", (20150529), URL: http://meeting.ascopubs.org/cgi/content/abstract/33/18_suppl/LBA6008, (20161003), XP055307194 | - |
| OPPOSITION | - Siewert T., Et Al., "Antitumor Activity of the anti-PD-1 AntibodyPembrolizumab in biomarker-unselected Patientswith R/M Head and Neck Cancer: Preliminary Results from the KEYNOTE-012 Expansion Cohort", ASCO Annual Meeting 2015, (20150529), pages 1 - 16, XP055857285 | - |
| OPPOSITION | - SIEWERT T. et al., "Antitumor Activity of the anti-PD-1 AntibodyPembrolizumab in biomarker-unselected Patientswith R/M Head and Neck Cancer: Preliminary Results from the KEYNOTE-012 Expansion Cohort", ASCO Annual Meeting 2015, (20150529), pages 1 - 16, XP055857285 | - |
| OPPOSITION | - STARR P., "Encouraging Results for Pembrolizumab in Head and Neck Cancer", Emerging Therapies, (20150800), vol. 8, page 16, XP055857318 | - |
| OPPOSITION | - Steven Francis Powell, Stephen V. Liu , Ammar Sukari , Christine H. Chung , Joshua Bauml , Robert I. Haddadchristine K. Gause , Michelle Niewood , Linda L. Gammage , Holly Brown , Amy Meister , Jonathan D. Cheng , Mark M. Gitau, "KEYNOTE-055: A phase II trial of single agent pembrolizumab in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) who have failed platinum and cetuximab.", Meeting Abstract TPS3094 | 2015 ASCO Annual Meeting I DEVELOPMENTAL THERAPEUTICS—IMMUNOTHERAPY, (20150101), XP055865483 | - |
| OPPOSITION | - "Study of Pembrolizumab (MK-3475) in Participants 'With Advanced Solid Tumors (MK-3475-012/KEYNOTE-012)", Clinical Trial No. NCT01848834, (20160616), XP55857327 | - |
| OPPOSITION | - Tabernero Josep, "Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic CRC, gastric cancer (GC), SCCHN, or other tumors.", Journal of Clinical Oncology, (20130531), pages 1 - 4, Journal of Clinical Oncology, URL: https://ascopubs.org/doi/abs/10.1200/jco.2013.31.15_suppl.3622, (20211115), XP055861248 | - |
| OPPOSITION | - Tanguy Y. Seiwert et al, "Antitumor activity and safety of pembrolizumab in patients (pts) with advanced squamous cell carcinoma of the head and neck (SCCHN): Preliminary results from KEYNOTE-012 expansion cohort", Journal of Oncology, (20150620), vol. 33, no. 18, XP055857341 | - |
| OPPOSITION | - URBAN et al., "What Is the Best Treatment for Patients With Human Papillomavirus-Positive and -NegativeOropharyngeal Cancer?", Cancer, (20140515), vol. 120, pages 1462 - 1470, XP055857331 | - |
| OPPOSITION | - Vietia D., Liuzzi J., Avila M., De Guglielmo Z., Prado Y., Correnti M., "Human papillomavirus detection in head and neck squamous cell carcinoma", Ecancer Medical Science, (20141023), vol. 8, no. 475, pages 1 - 8, XP055857333 | - |
| OPPOSITION | - Ward M J, Et Al, "Tumour-infiltrating lymphocytes predict for outcome in HPV-positive oropharyngeal cancer", British Journal of Cancer, (20140101), vol. 110, no. 2, pages 489 - 500, XP055861480 | - |
| OPPOSITION | - Wendling Patrice, "Pembrolizumab active in head and neck cancer, regardless of HPV status", MDedge Hematology and Oncology, (20150530), pages 1 - 4, MDedge Hematology and Oncology, URL: https://www.mdedge.com/hematology-oncology/article/100061/head-neck-cancers/pembrolizumab-active-head-and-neck-cancer, (20211119), XP055863541 | - |
| OPPOSITION | - ZARAVINOS, "An updated overview of HPV-associated head and neck carcinomas", Oncotarget, (20140000), vol. 5, pages 3956 - 3969, XP055857286 | - |
| OPPOSITION | - ZAVARINOS, "An updated overview of HPV-associated head and neck carcinomas", Oncotarget, (20140501), vol. 5, pages 3956 - 3969, XP055857286 | - |
| OPPOSITION | - David F. Mcdermott, Michael B. Atkins, "PD-1 as a potential target in cancer therapy", Cancer Medicine, Wiley, (20130721), doi:10.1002/cam4.106, ISSN 20457634, pages n/a - n/a, XP055157252 | |
| OPPOSITION | - Kelly Y Kim, James S Lewis, Zhong Chen, "Current status of clinical testing for human papillomavirus in oropharyngeal squamous cell carcinoma : Clinical HPV testing in OPSCC", The Journal of Pathology: Clinical Research, Wiley, (20181001), vol. 4, no. 4, doi:10.1002/cjp2.111, ISSN 2056-4538, pages 213 - 226, XP055726733 | |
| OPPOSITION | - Damien Urban; June Corry; Danny Rischin, "What is the best treatment for patients with human papillomavirus-positive and -negative oropharyngeal cancer?", Cancer, American cancer society , Philadelphia , PA, US, US , (20140227), vol. 120, no. 10, doi:10.1002/cncr.28595, ISSN 0008-543X, pages 1462 - 1470, XP071127521 | |
| OPPOSITION | - Patel Jaimin J., Et Al, "Impact of PD‐L1 expression and human papillomavirus status in anti‐PD1/PDL1 immunotherapy for head and neck squamous cell carcinoma—Systematic review and meta‐analysis", HEAD AND NECK., WILEY, NEW YORK, NY., US, US , (20200401), vol. 42, no. 4, doi:10.1002/hed.26036, ISSN 1043-3074, pages 774 - 786, XP055858771 | |
| OPPOSITION | - VENUTI et al., "HPV Detection Methods in Head and Neck Cancer", Head and Neck Pathol, (20120000), vol. 6, no. suppl 1, pages S63 - S74, XP035083545 | |
| OPPOSITION | - CHEN, Z. W. et al., "Equivocal p16 immunostaining in squamous cell carcinoma of the head and neck: staining patterns are suggestive of HPV status", Head and neck pathology, (20120000), vol. 6, no. 4, doi:10.1007/s12105-012-0382-3, pages 422 - 429, XP035140659 | |
| OPPOSITION | - Ukpo Odey C., Thorstad Wade L., Lewis James S., "B7-H1 Expression Model for Immune Evasion in Human Papillomavirus-Related Oropharyngeal Squamous Cell Carcinoma", Head and Neck Pathology, Springer US, Boston, Boston , (20130601), vol. 7, no. 2, doi:10.1007/s12105-012-0406-z, ISSN 1936-055X, pages 113 - 121, XP055863578 | |
| OPPOSITION | - Machiels J.-P. et al, "Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up", Annals of Oncology, Kluwer Dordrecht, NL, NL , (20201101), vol. 31, no. 11, doi:10.1016/j.annonc.2020.07.011, ISSN 0923-7534, pages 1462 - 1475, XP055861428 | |
| OPPOSITION | - Suzanne l. Topalian, Charles g. Drake, Drew m. Pardoll, "Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy", CANCER CELL, US , (20150401), vol. 27, no. 4, doi:10.1016/j.ccell.2015.03.001, ISSN 1535-6108, pages 450 - 461, XP055372181 | |
| OPPOSITION | - JOEL SUNSHINE et al., "PD-1/PD-L1 inhibitors", Current Opinion in Pharmacology, (20150801), vol. 23, doi:10.1016/j.coph.2015.05.011, pages 32 - 38, XP055304528 | |
| OPPOSITION | - Joel Sunshine, Janis M Taube, "PD-1/PD-L1 inhibitors", CURRENT OPINION IN PHARMACOLOGY, ELSEVIER SCIENCE PUBLISHERS,, NL, NL, (20150801), vol. 23, doi:10.1016/j.coph.2015.05.011, ISSN 1471-4892, pages 32 - 38, XP055304528 | |
| OPPOSITION | - SUNSHINE et al., "PD-1/PD-L1 inhibitors", Current Opinion in Pharmacology, (20150401), vol. 23, doi:10.1016/j.coph.2015.05.011, pages 32 - 38, XP055304528 | |
| OPPOSITION | - SWAIKA et al., "Current state of anti-PD-Ll and anti-PD-1 agents in cancer therapy", Molecular Immunology, (20150305), vol. 67, doi:10.1016/j.molimm.2015.02.009, pages 4 - 17, XP029246897 | |
| OPPOSITION | - GILDENER-LEAPMAN et al., "Promising systemic immunotherapies in head and neck squamous cell carcinoma", Oral Oncology, (20130000), vol. 49, doi:10.1016/j.oraloncology.2013.09.009, pages 1089 - 1096, XP055759187 | |
| OPPOSITION | - DAN P. ZANDBERG et al., "T he role of the PD-L1 :PD-1 pathway in squamous cell carcinoma of the head and neck", Oral Oncology, (20140701), vol. 50, no. 7, doi:10.1016/j.oraloncology.2014.04.003, pages 627 - 632, XP055304459 | |
| OPPOSITION | - Dan P. Zandberg, Scott E. Strome, "The role of the PD-L1:PD-1 pathway in squamous cell carcinoma of the head and neck", ORAL ONCOLOGY, ELSEVIER SCIENCE, OXFORD, GB, GB , (20140701), vol. 50, no. 7, doi:10.1016/j.oraloncology.2014.04.003, ISSN 1368-8375, pages 627 - 632, XP055304459 | |
| OPPOSITION | - Dan P. Zandberg, Scott E. Strome, "The role of the PD-L1:PD-1 pathway in squamous cell carcinoma of the head and neck", ORAL ONCOLOGY, ELSEVIER SCIENCE, OXFORD, GB, GB, (20140701), vol. 50, no. 7, doi:10.1016/j.oraloncology.2014.04.003, ISSN 1368-8375, pages 627 - 632, XP055304459 | |
| OPPOSITION | - Dan P. Zandberg, Scott E. Strome, "The role of the PD-L1:PD-1 pathway in squamous cell carcinoma of the head and neck", ORAL ONCOLOGY, GB, (20140701), vol. 50, no. 7, doi:10.1016/j.oraloncology.2014.04.003, ISSN 1368-8375, pages 627 - 632, XP055304459 | |
| OPPOSITION | - ZANDBERG, D. P. et al., "The role of the PD-L1:PD-1 pathway in squamous cell carcinoma of the head and neck", Oral Oncol, (20140000), vol. 50, no. 7, doi:10.1016/j.oraloncology.2014.04.003, pages 627 - 632, XP055304459 | |
| OPPOSITION | - ZANDBERG et al., "The role of the PD-L1:PD-1 pathway in squamous cell carcinoma of the head and neck", Oral Oncology, (20140000), vol. 50, no. 7, doi:10.1016/j.oraloncology.2014.04.003, pages 627 - 632 1st July 2014, XP055304459 | |
| OPPOSITION | - Mark S. Swanson, Uttam K. Sinha, "Rationale for combined blockade of PD-1 and CTLA-4 in advanced head and neck squamous cell cancer - Review of current data", ORAL ONCOLOGY, GB, (20150101), vol. 51, no. 1, doi:10.1016/j.oraloncology.2014.10.010, ISSN 1368-8375, pages 12 - 15, XP055553654 | |
| OPPOSITION | - SWANSON et al., "Rationale for combined blockade of PD-1 and CTLA-4 in advanced head and neck squamous cell cancer - Review of current data", Oral Oncology, (20141028), vol. 51, doi:10.1016/j.oraloncology.2014.10.010, pages 12 - 15, XP055553654 | |
| OPPOSITION | - Ferris Robert L., Et Al, "Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression", ORAL ONCOLOGY, ELSEVIER SCIENCE, OXFORD, GB, GB , (20180601), vol. 81, doi:10.1016/j.oraloncology.2018.04.008, ISSN 1368-8375, pages 45 - 51, XP055858760 | |
| OPPOSITION | - SEIWERT et al., "Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial", Lancet Oncology, vol. 17, doi:10.1016/S1470-2045(16)30066-3, (20160527), pages 956 - 965, XP029625468 | |
| OPPOSITION | - BARBER DANIEL L ET AL, "Restoring function in exhausted CD8 T cells during chronic viral infection.", Nature, London , (20060209), vol. 439, no. 7077, doi:10.1038/nature04444, ISSN 0028-0836, pages 682 - 687, XP002419629 | |
| OPPOSITION | - HERBST et al., "Predictive correlates of response to the anti-PD-L1 antibody 26th November MPDL3280A in cancer patients", Nature, (20140000), vol. 5157528, doi:10.1038/nature14011, pages 563 - 567, XP055262130 | |
| OPPOSITION | - ROY S. HERBST et al., "Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients", Nature, (20141126), vol. 515, no. 7528, doi:10.1038/nature14011, pages 563 - 567, XP055262130 | |
| OPPOSITION | - Haidong Dong, Scott E. Strome, Diva R. Salomao, Hideto Tamura, Fumiya Hirano, Dallas B. Flies, Patrick C. Roche, Jun Lu, Gefeng Zhu, Koji Tamada, Vanda A. Lennon, Esteban Celis & Lieping Chen, "Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion.", Nature Medicine, New York , (20020624), vol. 8, no. 8, doi:10.1038/nm730, ISSN 1078-8956, pages 793 - 800, XP002397368 | |
| OPPOSITION | - Graham Sheila v., "The human papillomavirus replication cycle, and its links to cancer progression: a comprehensive review", CLINICAL SCIENCE., BIOCHEMICAL SOCIETY AND THE MEDICAL RESEARCH SOCIETY, LONDON,, GB, GB , (20170901), vol. 131, no. 17, doi:10.1042/CS20160786, ISSN 0143-5221, pages 2201 - 2221, XP055863592 | |
| OPPOSITION | - VERMORKEN, J. B., "Platinum Based Chemotherapy plus Cetuximab in Head and 11th Neck Cancer", New England Journal of Medicine, (20080900), vol. 359, doi:10.1056/NEJMoa0802656, pages 1116 - 1127, XP055243458 | |
| OPPOSITION | - TOPALIAN, S. L. et al., "Safety, Activity, and Immune Correlates of Anti- PD-1 Antibody in Cancer", New England Journal of Medicine, (20120000), vol. 366, no. 26, doi:10.1056/NEJMoa1200690, pages 2443 - 2454, XP055098235 | |
| OPPOSITION | - Robert L. Ferris, George Blumenschein, Jerome Fayette, Joel Guigay, A. Dimitrios Colevas, Lisa Licitra, Kevin Harrington, Stefan Kasper, Everett E. Vokes, Caroline Even, Francis Worden, Nabil F. Saba, Lara C. Iglesias Docampo, Robert Haddad, Tamara Rordorf, Naomi Kiyota, Makoto Tahara, Manish Monga, Mark Lynch, William J. Geese, Justin Kopit, James W. Shaw, Maura L. Gillison, "Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck", The New England journal of medicine, Massachusetts Medical Society, US, US , (20161110), vol. 375, no. 19, doi:10.1056/NEJMoa1602252, ISSN 0028-4793, pages 1856 - 1867, XP055727440 | |
| OPPOSITION | - IWAI YOSHIKO ET AL, "Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade.", Proceedings of the National Academy of Sciences, (20020917), vol. 99, no. 19, doi:10.1073/pnas.192461099, ISSN 0027-8424, pages 12293 - 12297, XP002398159 | |
| OPPOSITION | - Vermorken J.B., Specenier P., "Optimal treatment for recurrent/metastatic head and neck cancer", Annals of Oncology, Kluwer Dordrecht, NL, NL , (20101001), vol. 21, doi:10.1093/annonc/mdq453, ISSN 0923-7534, pages vii252 - vii261, XP055861427 | |
| OPPOSITION | - Fury M et al, "Clinical Activity and Safety of Medi4736, an Anti-Pd-L1 Antibody, in Patients with Head and Neck Cancer", Annals of Oncology, Kluwer Dordrecht, NL, NL , (20140901), vol. 25, doi:10.1093/annonc/mdu340.3, ISSN 0923-7534, pages iv341 - 356, XP055858816 | |
| OPPOSITION | - G. K. Philips, M. Atkins, "Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies", International Immunology, Oxford University Press, GB, GB , (20150101), vol. 27, no. 1, doi:10.1093/intimm/dxu095, ISSN 0953-8178, pages 39 - 46, XP055217958 | |
| OPPOSITION | - PHILIPS et al., "Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies", 16th October International Immunology, (20140000), vol. 27, no. 1, doi:10.1093/intimm/dxu095, pages 39 - 46, XP055217958 | |
| OPPOSITION | - Barraclough Helen, Simms Lorinda, Govindan Ramaswamy, "Biostatistics Primer: What a Clinician Ought to Know: Hazard Ratios", Journal of Thoracic Oncology, Elsevier Inc., US, US , (20110601), vol. 6, no. 6, doi:10.1097/JTO.0b013e31821b10ab, ISSN 1556-0864, pages 978 - 982, XP055865462 | |
| OPPOSITION | - Jordan Richard C., Et Al, "Validation of Methods for Oropharyngeal Cancer HPV Status Determination in US Cooperative Group Trials", AMERICAN JOURNAL OF SURGICAL PATHOLOGY., RAVEN PRESS, NEW YORK, NY., US, US , (20120701), vol. 36, no. 7, doi:10.1097/PAS.0b013e318253a2d1, ISSN 0147-5185, pages 945 - 954, XP055858801 | |
| OPPOSITION | - Field Nigel, Lechner Matt, "Exploring the implications of HPV infection for head and neck cancer", SEXUALLY TRANSMITTED INFECTIONS, BMJ PUBLISHING GROUP, LONDON, GB, GB , (20150601), vol. 91, no. 4, doi:10.1136/sextrans-2014-051808, ISSN 1368-4973, pages 229 - 230, XP055861293 | |
| OPPOSITION | - LYFORD-PIKE et al., "Evidence for a role of the PD-1 :PD-L1 pathway in immune resistance of HPV- associated head and neck squamous cell carcinoma", Cancer Res., (20130315), vol. 73, no. 6, doi:10.1158/0008-5472.CAN-12-2384, pages 1733 - 1741, XP055179352 | |
| OPPOSITION | - LYFORD-PIKE et al., "Evidence for a Role of the PD-1:PD-L1 Pathway in Immune Resistance of HPV-Associated Head and Neck Squamous Cell Carcinoma", Cancer Research, (20130000), vol. 73, doi:10.1158/0008-5472.CAN-12-2384, pages 1733 - 1741, XP055179352 | |
| OPPOSITION | - LYFORD-PIKE, S. et al., "Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma", Cancer Res, (20130000), vol. 73, no. 6, doi:10.1158/0008-5472.CAN-12-2384, pages 1733 - 1741, XP055179352 | |
| OPPOSITION | - Lyford-Pike Sofia et al, "Evidence for a Role of the PD-1:PD-L1 Pathway in Immune Resistance of HPV-Associated Head and Neck Squamous Cell Carcinoma", Cancer research, American Association for Cancer Research, (20130315), vol. 73, no. 6, doi:10.1158/0008-5472.CAN-12-2384, ISSN 00085472, pages 1733 - 1741, XP055179352 | |
| OPPOSITION | - S. Lyford-Pike, S. Peng, G. D. Young, J. M. Taube, W. H. Westra, B. Akpeng, T. C. Bruno, J. D. Richmon, H. Wang, J. A. Bishop, L. Chen, C. G. Drake, S. L. Topalian, D. M. Pardoll, S. I. Pai, "Evidence for a Role of the PD-1:PD-L1 Pathway in Immune Resistance of HPV-Associated Head and Neck Squamous Cell Carcinoma", Cancer research, (20130315), vol. 73, no. 6, doi:10.1158/0008-5472.CAN-12-2384, ISSN 00085472, pages 1733 - 1741, XP055179352 | |
| OPPOSITION | - S. Lyford-Pike, S. Peng, G. D. Young, J. M. Taube, W. H. Westra, B. Akpeng, T. C. Bruno, J. D. Richmon, H. Wang, J. A. Bishop, L. Chen, C. G. Drake, S. L. Topalian, D. M. Pardoll, S. I. Pai, "Evidence for a Role of the PD-1:PD-L1 Pathway in Immune Resistance of HPV-Associated Head and Neck Squamous Cell Carcinoma", Cancer research, American Association for Cancer Research, (20130315), vol. 73, no. 6, doi:10.1158/0008-5472.CAN-12-2384, ISSN 00085472, pages 1733 - 1741, XP055179352 | |
| OPPOSITION | - C. Badoual et al, "PD-1-Expressing Tumor-Infiltrating T Cells Are a Favorable Prognostic Biomarker in HPV-Associated Head and Neck Cancer", Cancer research, American Association for Cancer Research, US, US , (20130101), vol. 73, no. 1, doi:10.1158/0008-5472.CAN-12-2606, ISSN 0008-5472, pages 128 - 138, XP055326633 | |
| OPPOSITION | - P. A. Ott, F. S. Hodi, C. Robert, "CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients", Clinical Cancer Research, Association for Cancer Research, (20131001), vol. 19, no. 19, doi:10.1158/1078-0432.CCR-13-0143, ISSN 10780432, pages 5300 - 5309, XP055200528 | |
| OPPOSITION | - KECK et al., "Integrative analysis of head and neck cancer identifies two biologically distinct HPV and three non-HPV subtypes", Clinical Cancer Research, (20140000), vol. 21, no. 4, doi:10.1158/1078-0432.CCR-14-2481, pages 870 - 881, XP055307196 | |
| OPPOSITION | - KECK et al., "Integrative Analysis of Head and Neck Cancer Identifies Two Biologically Distinct HPV and Three Non-HPV Subtypes", Clinical Cancer Research, (20141209), vol. 21, no. 4, doi:10.1158/1078-0432.CCR-14-2481, pages 870 - 881, XP055307196 | |
| OPPOSITION | - M. K. Keck et al, "Integrative Analysis of Head and Neck Cancer Identifies Two Biologically Distinct HPV and Three Non-HPV Subtypes", Clinical Cancer Research, Association for Cancer Research, (20150215), vol. 21, no. 4, doi:10.1158/1078-0432.CCR-14-2481, ISSN 1078-0432, pages 870 - 881, XP055307196 | |
| OPPOSITION | - Zhe Jin, "Immune-checkpoint inhibitor plus chemotherapy versus conventional chemotherapy for treatment of recurrent or metastatic head and neck squamous cell carcinoma: a systematic review and network meta-analysis", Therapeutic Advances in Medical Oncology, SAGE Publishing, (20200101), vol. 12, doi:10.1177/1758835920983717, ISSN 1758-8359, page 175883592098371, XP093165825 | |
| OPPOSITION | - SRIVASTAVA et al., "Anti-PD-1 mAb pre-radiotherapy (RT) loading dose and fractionated RT induce better tumor-specific immunity and tumor shrinkage than sequential administration in an HPV+ head and neck cancer model", Journal for ImmunoTherapy of Cancer, (20151104), vol. 3, no. Suppl 2, page P314, XP021235475 | |
| OPPOSITION | - GANGADHAR et al., "Clinical applications of PD-1-based therapy: a focus on pembrolizumab ( MK -3475) in the management of melanoma and other tumor types", OncoTargets and Therapy, (20150422), vol. 8, doi:10.2147/OTT.S53164, pages 929 - 937, XP055202068 | |
| OPPOSITION | - El Rassy Elie, Assi Tarek, Bakouny Ziad, El Karak Fadi, Pavlidis Nicholas, Ghosn Marwan, "Comparison of second-line treatments of recurrent and/or metastatic squamous cell carcinoma of the head and neck", Future oncology, Future Medicine Ltd., UK, UK , (20190123), vol. 15, no. 8, doi:10.2217/fon-2018-0663, ISSN 1744-8301, pages 909 - 923, XP009554959 | |
| OPPOSITION | - PAI, "Adaptive immune resistance in HPV-associated head and neck squamous cell carcinoma", OncoImmunology, (20130000), vol. 2, no. 5, doi:10.4161/onci.24065, pages 1 - 2, XP055326362 | |
| OPPOSITION | - PAI, S. I., "Adaptive immune resistance in HPV-associated head and neck squamous cell carcinoma", Oncoimmunology, (20130000), vol. 2, no. 5, doi:10.4161/onci.24065, page e24065, XP055326362 | |
| OPPOSITION | - Sara I. Pai, "Adaptive immune resistance in HPV-associated head and neck squamous cell carcinoma", OncoImmunology, (20130501), vol. 2, no. 5, doi:10.4161/onci.24065, page e24065, XP055326362 | |
| OPPOSITION | - Lewis James S, "Human Papillomavirus Testing in Head and Neck Carcinomas: Guideline From the College of American Pathologists", Archives of pathology & laboratory medicine (1976), College of American Pathologists, United States, United States, doi:10.5858/arpa.2017-0286-CP, (20180501), pages 559 - 597, Archives of pathology & laboratory medicine (1976), URL: https://allen.silverchair-cdn.com/allen/content_public/journal/aplm/142/5/10.5858_arpa.2017-0286-cp/2/arpa_2017-0286-cp.pdf?Expires=1640002123&Signature=R6f2t5ch38h5LtOXGPM3FFqYbzRjMnZWCj~tUSaP2XWwoI190aKcfpx916bxZFuISAl-zakSMQIaeOYVGFuGz3z7gD3EnRM6AzXdpNEucFCBWm0SOkfzabn7qij6CnuuIxfmLiD5w2gUXmxmBWr2lvpZWzIwJlUUIzBWvXLZVWvexSx198BSl9nt0BtAFkeKyKRCNvFhKnMk7Dh-liMERTslAd7Yj~egmBNqUGv0nSbI3ZsVattliRkbUan3x6Lac6VdWBEBIpOId8898OPlO8i-7URcBoZJ3YO6aqFEbLJ~TcdzomNlNuqtFx7XLR1Bn2165QlVZU3VjD0Kk~-6Lg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA, (20211115), XP055861429 | |
